The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Open accessAbstract
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-X L proteolysis-targeting chimera (PROTAC), that targets BCL-X L to the Von Hippel-Lindau (VHL) E3 ligase for degradation. We found that DT2216 was more potent against various BCL-X L-dependent leukemia and cancer cells but considerably less toxic to platelets than ABT263 in vitro because VHL is poorly expressed in platelets. In vivo, DT2216 effectively inhibits the growth of several xenograft tumors as a single agent or in combination with other chemotherapeutic agents, without causing appreciable thrombocytopenia. These findings demonstrate the potential to use PROTAC technology to reduce on-target drug toxicities and rescue the therapeutic potential of previously undruggable targets. Furthermore, DT2216 may be developed as a safe first-in-class anticancer agent targeting BCL-X L.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The use of a navitoclax PROTAC facilitated the rapid and specific degradation of BCL-2, resulting in apoptosis of cancer cells with less off-target lysis.”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [76]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the therapeutic window of navitoclax is improved by utilizing an approach that degrades certain BCL-2 family members instead of just inhibiting their function (76).”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“several PROTACs have shown promising preclinical results in the treatment of hematologic malignancies [3, 4, 44]”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“DT2216 has shown promising antitumor activities in BCL-XL-dependent hematologic cancers as a single agent therapy and in multiple solid tumors when combined with conventional chemotherapy [8–10].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, our group has reported platelet-sparing targeting of BCL-XL by proteolysis targeting chimeras (PROTACs) exemplified by DT2216.”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This potentiates the antitumour activity of ABT263 while suppressing its side effects on platelets in which VHL is poorly expressed [120].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [120]
The cited source says what the claim attributes to it.
In the citing paper
“Linkage of ABT263 to a von Hippel -Lindau (VHL) E3 ligasetargeting moiety results in degradation rather than inhibition of BCL-XL activity itself.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [120]
The cited source says what the claim attributes to it.
In the citing paper
“DT2216, a VHL-recruiting BCL-xL PROTAC that achieved potent antitumor activity without the severe thrombocytopenia observed with navitoclax87”
From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [87]
In the citing paper
“In 2019, Zhou’s team identified DT2216 (200), the first selective Bcl-xL degrader based on ABT263 (navitoclax), by linking ABT263 to VHL ligands (Table 4).”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“In vivo, DT2216 effectively inhibited the growth of multiple xenograft tumors without causing significant thrombocytopenia.492”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“DT2216 exhibited high potency against various Bcl-xL-dependent leukemia and cancer cells while demonstrating lower platelet toxicity than ABT263.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [492]
In the citing paper
“For instance, it was shown that a PROTAC that co-opts the E3 ligase VHL to induce the degradation of BCL-XL can spare the thrombocytopenia associated with systemic BCL-XL inhibition.72”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [72]
In the citing paper
“A remarkable example is the low expression of VHL in platelets”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [152]
In the citing paper
“degradation of BCL-xL by the VHL-recruiting PROTAC DT2216 (ref.152) was spared in platelets, thus resulting in reduced platelet-driven toxicity and an improved therapeutic index compared with a BCL-xL inhibitor78,153.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [152]
In the citing paper
“A number of PROTACs have been developed to target various POIs that are involved in the tumorigenesis and progression of hematologic malignancies, such as anaplastic lymphoma kinase (ALK) [5], Bcl-xL [4], BCR-ABL [6], Bruton’s tyrosine kinase (BTK) [7], BRD4 [8], CDK-6 [9], FMS-like tyrosine kinase-3 (FLT-3) [10], HDAC6 [11], and signal transducer and activator of transcription 3 (STAT3) [3].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Moreover, DT2216 potently degraded Bcl-xL protein and inhibited MOLT-4 T-ALL in vitro and in vivo.”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“DT2216, a representative PROTAC that hijacks the VHL E3 ligase to achieve tissue/cell-selective degradation of Bcl-xL, was found to be more potent against Bcl-xL-dependent tumor cells and less toxic against platelets in comparison to conventional Bcl-xL inhibitors.”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Fourth, it is possible to achieve tumor-specific/selective degradation of a POI with PROTACs by using ligands for cell type- and/or tumor-specific/selective E3 ligases [2, 4].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Although numerous PROTACs have been generated in the past few years, only a few of them are tumor-selective to avoid normal tissue toxicity, including platelet sparing Bcl-xL PROTACs reported by us recently by taking advantage of the E3 ligases that are barely expressed in platelets [4, 60–63].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“The prolonged depletion of a target by PROTACs may cause on-target toxicities if a POI is indispensable for normal functions [4].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Therefore, profiling the changes in global protein expression by proteomics will be helpful to appreciate the potential off-target toxicities of PROTACs [3, 4, 43].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Bcl-xL PROTACs discussed above are an example of this approach [4, 61–63].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [4]
In the citing paper
“Recently, we reported the first use of PROTAC technology to selectively target anti-apoptotic BCL-XL protein in tumor cells with reduced platelet toxicity by employing VHL or CRBN E3 ligases that are minimally expressed in platelets [34, 35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“in the case of our BCL-XL PROTACs the prolonged degradation of BCL-XL may be advantageous because BCL-XL exhibits functional redundancy in normal tissues except platelets, and therefore its prolonged depletion accounts for better therapeutic efficacy [35, 80, 81].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“Recently, we converted a dual inhibitor of BCL-XL and BCL-2, named ABT263 (or navitoclax), into selective VHL-based BCL-XL PROTACs, which provides further evidence that promiscuous inhibitors can be converted into target-specific PROTACs [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“we have shown that VHL is differentially expressed between tumor cells and platelets, which helped us to design platelet-sparing BCL-XL PROTACs [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“We were the first to report tumor-selective and platelet-sparing BCL-XL PROTACs by taking advantage of the E3 ligases that are barely expressed in platelets [34, 35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“In addition, there are several other PROTAC drug candidates with promising preclinical data that can potentially be tested in clinical trials in the near future [1, 35, 40].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“The development of PROTACs based on tissue-specific and tumor-selective E3 ligases could be one such potential strategy that can revolutionize the field of PROTACs as cancer therapeutics, as we recently demonstrated [35, 36].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
In the citing paper
“Some of the PROTACs, such as PROTACs targeting BCL-XL and ALK [35, 105], have broad-spectrum antitumor activities, which can effectively kill leukemia and solid tumor cells in vitro and in xenograft models.”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Universal sample preparation method for proteome analysis
Wiśniewski, J. R., Zougman, A., Nagaraj, N., & Mann, M. (2009) · Nature Methods · doi:10.1038/nmeth.1322 · Cited by 8,352
A statistical model for identifying proteins by tandem mass spectrometry.
Nesvizhskii, A., Keller, A., Kolker, E., & Aebersold, R. (2003) · Analytical Chemistry · doi:10.1021/ac0341261 · Cited by 4,902
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Cited by
Sorted by citations
Items 501–600 of 698
Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems
Yao, T., Zhou, Z., Wang, G., Zhu, Z.-Y., & Li, X.-N. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01853-2 · Cited by 5
Ma, T., Luo, T., & Wang, M. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.010 · Cited by 3
Application of mass spectrometry for the advancement of PROTACs
Hao, Y., Zhang, B., & Chen, R. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116829 · Cited by 4
Chang, L.-C., Yin, M. T., Laird, G. M., Ritter, K. D., Shah, J. G., & Debnath, A. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062772 · Cited by 3
Han, W., Guan, M., Liao, B., Han, X., Li, K., Chen, Q., Guo, X., Niu, Y., Zhu, Y., & Bai, D. (2025) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2025e14408 · Cited by 3
Manzella, G., Moonamale, D. C., Römmele, M., Bode, P. K., Wachtel, M., & Schäfer, B. W. (2021) · Neoplasia · doi:10.1016/j.neo.2021.07.001 · Cited by 4
The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis
Wei, Y., Wu, B., Liu, M., & Cui, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168870 · Cited by 4
Therapeutics targeting BCL2 family proteins
Dai, H., Meng, X. W., Ye, K., Jia, J., & Kaufmann, S. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00007-5 · Cited by 2
The BCL-2 Family Proteins: Insights Into Their Mechanism of Action and Therapeutic Potential
van Delft, M. F., & Dewson, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00141-3 · Cited by 3
Pharmacology of PROTAC Degrader Molecules
Pike, A., Guzzetti, S., Gutierrez, P. M., & Scott, J. S. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch11 · Cited by 3
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H.-Y., & Huang, H. (2021) · doi:10.1101/2021.03.08.434493 · Cited by 2
Self-citationPalyada, K., Hukkanen, R. R., Leuenroth-Quinn, S., Vitsky, A., Peterson, R. E., Stamp, K., Hoover, C., & Volak, L. P. (2024) · Toxicologic Pathology · doi:10.1177/01926233241300452 · Cited by 2
Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma
Mi, W., Cigliano, A., Galleri, G., Gigante, I., Steinmann, S. M., Cibali, E., Serra, M., Pes, G. M., Schlösser, D., Pizzuto, E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101416 · Cited by 3
Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy
Li, R., Zhang, S., Xu, Y., Liu, R., & Dai, Z. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00305 · Cited by 3
Elimination of docetaxel-induced senescence attenuates malignant progression in RB1-deficient CRPC
Su, H., Huang, L., Xia, W., Tang, D. G., Zhou, J., & Yang, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01126-w · Cited by 3
Pandur, E., Schenk, P., Kulcsár, G., Gulyás‐Fekete, G., Sipos, K., & Huber, I. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04077-2 · Cited by 2
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4
Wang, P., Zhao, H., Zhang, S., Guo, Y., Xing, X., Zhou, S., Yang, S., Wang, F., Chen, W., Wang, J., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.11.038 · Cited by 2
Vardon, A., Haston, S., Hamdi, H., Cooksley, G., Guiho, R., Carvalho, D. M., Carter, R., Boult, J. K. R., Gharai, D., Cloete, I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32676-6 · Cited by 3
Self-citationVänttinen, I., Saad, J. J., Ruokoranta, T. M., Kytölä, S., Qin, G., Tercan, B., Ettala, P., Partanen, A., Pyörälä, M., Rimpiläinen, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70282 · Cited by 3
Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma
Zeng, Q., Zhang, Y., Yang, Y., Liu, X., Dong, X., Pan, Y., Hu, L., Zhang, A., Yang, J., Luo, Q., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04671-9 · Cited by 2
Self-citationWei, Q., Zhang, J., Chen, J., Cai, X., 周金培, Wang, B., Zhang, H., & Cao, P. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118667 · Cited by 2
Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry
Gadallah, M. I., Nonhof, K. L., Nayak, D., Zhang, P., Dioli, O. E., Zheng, G., Olsen, S. K., Zhou, D., & Brodbelt, J. S. (2026) · Chemical Science · doi:10.1039/d5sc07400b · Cited by 4
Self-citationMiyan, J., Vudatha, V., Cao, L., Zhang, P., Zheng, G., Zheng, L., Trevino, J., Zhou, D., & Khan, S. (2026) · Cancers · doi:10.3390/cancers18060920 · Cited by 2
Self-citationDiscovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity
Tu, Y., Cai, X., Tao, Z., Zhang, R., Li, X., Chen, B., Zhang, H., Hu, X., Ke, J., Chen, X., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02925-2 · Cited by 3
Identification of KLHL12 Ligands Using Fragment-Based Methods
Waterson, A. G., Vadukoot, A. K., Jana, S., Cui, J., Luong, K., Rietz, T. A., Madrigal‐Carrillo, E. A., Lehmann, B. D., Sensintaffar, J., Zhao, B., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02931 · Cited by 2
Nanoplatform‐Based Delivery Systems for PROTACs
Che, W., Wang, X., Chen, S., Du, M., Wang, W., Liu, D., Fan, S., Wu, Z., Wu, Y., Dong, Y., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70301 · Cited by 2
Pretargeted PROTAC Strategy Enables Precise Tumor Target Degradation via Self-Assembling Peptides
Wu, Q., Zhang, C., Li, Y., Zhang, M., Yan, H., Xu, N., Tan, C., & Tan, Y. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c05907 · Cited by 2
Can PROTACs truly become oral drugs?
Alhafi, A., & Gupta, V. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104709 · Cited by 2
Targeted protein degradation: bridging chemical biology and clinical translation
Zhang, Y., Fu, J.-W., Liu, Y., Wu, R. Y., Liang, Y., Zhang, W., Yuan, T., Zhu, H., He, Q.-J., & Yang, B. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01861-2 · Cited by 2
Self-citationE3 ubiquitin ligases in nasopharyngeal carcinoma and implications for therapies
Zhou, Z., Zheng, K., Zhou, S., Yang, Y., Chen, J., & Jin, X. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02376-7 · Cited by 3
PROTAC degraders of FSP1 act as potent GPX4 sensitizers to induce ferroptosis for hepatoma treatment
Zhu, J., Tan, Q., Fan, S., Li, Y., Zhu, L., Hong, L., Wang, Y., Zhang, C., Chen, C., Kong, L., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111285 · Cited by 2
Procedural Physician-Scientists as Catalysts for Innovation in Team Science and Clinical Care
Khan, S. A., Schultz, K. S., & Ahuja, N. (2025) · Cancers · doi:10.3390/cancers17152468 · Cited by 2
Self-citationSmall-molecule degron mimetics for targeted protein degradation
Liu, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253026 · Cited by 2
Self-citationEmerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells
Lecky, E., Mukherji, A., German, R. M., Antonellis, G., Lin, J., Yorsz, M., McQueeney, K. E., Ryan, J. A., Ng, K., Sicińska, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg4128 · Cited by 2
Liu, X., Lei, M., Xue, Y., Li, H., Yin, J., Li, D., Shu, J., & Cai, C. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10488-5 · Cited by 2
Self-citationHallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis
Li, C., Wang, Q., Jiang, K., & Ye, Y. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107079 · Cited by 2
Ohtsu, A., Arai, S., Sawada, T., Kato, M., Maeno, Y., Miyazawa, Y., Fujizuka, Y., Sekine, Y., Koike, H., Matsui, H., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.083 · Cited by 2
Grubb, T. M., Maganti, S., Krill-Burger, J. M., Fraser, C. S., Stransky, L. A., Radivoyevitch, T., Sarosiek, K. A., Vázquez, F., Kaelin, W. G., & Chakraborty, A. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.29.478337 · Cited by 2
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL
Wang, N., Hakimi, A. A., & Chen, Y. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2104 · Cited by 1
Advancing proteolysis targeting chimeras toward clinical drug developments
Tian, X., Huang, C., Yin, L., & Yu, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00007-8 · Cited by 1
Targeted Degradation of ZBP1 with Covalent PROTACs for Anti‐Inflammatory Treatment of Infections
Huang, R., Hu, Y., Wang, Y., Zhang, S., Wang, Z., Pang, D., & Liu, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202423524 · Cited by 1
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Taliaferro, L. P., Buchsbaum, J. C., DiCarlo, A. L., Dixon, C. A., Macchiarini, F., Satyamitra, M. M., PrabhuDas, M., & Rudokas, M. W. (2025) · Radiation Research · doi:10.1667/rade-24-00263.1 · Cited by 1
Degraders of cell cycle- and antiapoptosis-related proteins
Zhang, Y., Dong, R., & Zhang, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00002-6 · Cited by 1
Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70427 · Cited by 2
Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2
Tang, H., Liao, Y., Yeh, T. Y., Nishibayashi, K., Rouhimoghadam, M., Yang, K., Li, C., de Gonzalez, R. S., Zhao, Y., Hawkins, N. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00020
Current Status of Molecularly Targeted Therapeutics in Blood Cancers
Kumala, C., Vu, L., & Fandy, T. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110512 · Cited by 1
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
Westaby, D., Jiménez-Vacas, J., Figueiredo, I., Welti, J., Gurel, B., Bogdan, D., Buroni, L., Neeb, A., Rekowski, J., Padilha, A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113985 · Cited by 1
A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis
Yang, B., Ma, L., Yang, X., Wen, J., Yin, W., Li, S., Ji, Y., Wang, Y., Cen, S., & Li, Y. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11393-2 · Cited by 2
Shah, R. D., Kingston, N. M., Fabbri, G., Saeh, J. C., Andersen, C. L., & Cheung, P. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105379 · Cited by 1
Xu, W., Chen, H., Gong, H., Zhao, T., Yang, Y., Wang, F., Huang, N., Yang, M., Gao, N., Li, H., et al. (2026) · Phytotherapy Research · doi:10.1002/ptr.70220 · Cited by 1
Cheng, J., Wang, H., Zhang, Y., & Liu, G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117802 · Cited by 1
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Benrashid, S., & Woyach, J. A. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00776-3 · Cited by 3
Wang, L., Tao, X., He, M., Lu, Y., Wang, Y., & Zhu, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109731 · Cited by 1
Won, H.-J., Baek, S. M., Lee, M. H., Park, J. H., Shin, J., Yang, Y., Jang, Y. H., Inn, K., & Kim, N. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501208 · Cited by 1
Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1
Sweileh, M. W. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06482-0 · Cited by 1
Gu, J., He, M., Wang, W., Hu, J., Yang, X., Lai, M., Li, S., Duan, X., Luo, Q., & Zhang, G. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105384 · Cited by 1
Clinical implications of proteostasis in cancer
Raj, S., & Babuta, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41553-1.00009-8 · Cited by 1
The BAX/BAK apoptotic checkpoint polices entry to therapy-induced senescence
Aldave, A. G., Venugopalan, V., Gunay, G., Hamsici, S., Ribeiro, R. R., Costigan, A., Gabrielyan, A., Efe-Cicek, H., & Martin, S. J. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.07.002 · Cited by 1
BCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers
Basuroy, T., Grubb, T. M., Sadagopan, A., Qin, X., Madison, K., Hall, A., Willard, B. B., Vanharanta, S., Sarosiek, K. A., Viswanathan, S. R., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09262-3 · Cited by 1
Wang, K., Zhu, W., Huang, W., Huang, K., Luo, H., Long, L., & Yi, B. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s463286 · Cited by 1
PROTACs in Treatment of Glioma
Kumar, S., & Maharshi, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_15 · Cited by 1
Toxicological Aspects of PROTACs
Pujari, R., & Soni, U. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_10 · Cited by 1
Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma
Ho, M. P., Skouradaki, E., Baritaki, S., Otumo, E., & Bonavida, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189395 · Cited by 1
Structural and Biophysical Principles of Degrader Ternary Complexes
Zollman, D., & Ciulli, A. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00014 · Cited by 3
唐, 庆., & 张, 莹. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1010841 · Cited by 1
Pharmacologic Features of Drugs Targeting BCL 2 Family Members
Lue, J. K., & O’Connor, O. A. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch11 · Cited by 1
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
RetractedEpithelial IL-2 is critical for NK cell-mediated cancer immunosurveillance in mammary glandsPreprint
Wang, L., Maharjan, C. K., Borcherding, N. C., Master, R. P., Mo, J., Tithi, T. I., Kim, M., Carelock, M. E., Master, A. P., Gibson-Corley, K. N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.25.591178 · Cited by 1
Self-citationSynthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastomaPreprint
Yin, J., Sun, B., Liu, M., Zhang, Y., Niu, R., Li, X., Wang, J., & Shi, B. (2024) · Research Square · doi:10.21203/rs.3.rs-4599552/v1 · Cited by 1
De novo designed bifunctional proteins for targeted protein degradationPreprint
Mylemans, B., Korona, B., Acevedo‐Jake, A. M., MacRae, A., Edwards, T. A., Huang, D. T. C., Wilson, A. J., Itzhaki, L. S., & Woolfson, D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.695915 · Cited by 2
Coiled-coil scaffolds for Targeted Protein DegradationPreprint
Korona, B., Mylemans, B., Acevedo‐Jake, A. M., Huang, D. T., Edwards, T. A., Wilson, A. J., Woolfson, D. N., & Itzhaki, L. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.695764 · Cited by 1
Identification of clofibric acid as a SYVN1 ligand for PROTAC developmentPreprint
Warren, J., Munakala, A., Zientek, K. D., Kim, K., Wilmarth, P. A., Reddy, A. P., Li, B. X., & Xiao, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.26.701774 · Cited by 1
Islam, S., Hussain, A., Alam, A., Ansari, M. O., Saeed, H., & Khan, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1812881 · Cited by 1
Self-citationBrinkmann, K., Waring, P., Glaser, S. P., Wimmer, V. C., Nhu, D., Whitehead, L. W., Delbridge, A. R. D., Lessène, G., Herold, M. J., Kelly, G. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.28.055665
VHL ligand binding increases intracellular level of VHLPreprint
Frost, J., Rocha, S., & Ciulli, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.12.439487
Apoptosis, necroptosis, and pyroptosis in health and disease
Liao, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00008-7
刘晓岗 (2010) · 视听界
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Epithelial-mesenchymal transition and resistance to EGFR inhibitors
Jacob, S., Kurupi, R., & Faber, A. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00009-7
Senotherapy as a Novel Therapeutic Method in Cancer Treatment: With a Focus on Head and Neck Cancer
Ziaei, H., & Harada, H. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_118
β-Catenin and its new partner FOXO3 shake T-ALL
Calvo, J., & Pflumio, F. (2023) · Blood · doi:10.1182/blood.2022018650
Fletcher-Sananikone, E., Kanji, S., Tomimatsu, N., Cristofaro, L. F. M. D., Kollipara, R. K., Saha, D., Floyd, J., Sung, P., Hromas, R., Burns, T. C., et al. (2023) · doi:10.1158/0008-5472.c.6513888.v1
Self-citationLeto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1
Chen, Y., Cai, Q., Pan, C., Liu, W., Li, L., Liu, J., Gao, M., Li, X., Wang, L., Rao, Y., et al. (2023) · doi:10.1158/2326-6066.c.6550587
Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer ImmunotherapyPreprint
Wang, L. A., Xiao, Y., Luo, Y., Master, R. P., Mo, J., Kim, M., Liu, Y., Patel, U. M., Li, X., Shaffer, D. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552650
Self-citationInsights into protein-bound uremic toxins in proximal tubule cell senescence and kidney fibrosis
Yang, Y. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1996
Tan, Y., Xin, L., Wang, Q., Xu, R., Tong, X., Chen, G., Ma, L., Yang, F., Jiang, H., Zhang, N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3699368/v1
Design of Mdm2 Protac Degraders with a Built-In Tumor-Targeting AbilityPreprint
Wang, Z., Yue, S., Chen, X., Li, J., Zhu, P., Chen, H., Qiu, F., Xie, D., Liang, Y., Li, D., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4845142
Bui, I., Vivarelli, S., Falzone, L., Libra, M., & Bonavida, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00002-6
Zhao, J., Bi, B., Li, Y., Zhou, S., Wang, Q., Chen, H.-X., Li, Z., Duan, Y., Luo, Y., Xu, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4780236/v1
Self-citationRibes, S., Nittinger, E., Tyrchan, C., & Mercado, R. (2024) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2024.100114
Role of PROTACs in Hematological Malignancies
Iqubal, A., Iqubal, M. K., Yadav, S., Arun, V. A., & Mishra, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_13
Clinical Development of PROTACs
Dubey, A., Pal, K., & Gota, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_9
Metadata
- Authors
- Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., Pei, J., Zhang, W., Sharma, A., McCurdy, C. R., Kuruvilla, V. M., Baran, N., Ferrando, A. A., Kim, Y.-M., Rogojina, A., Houghton, P. J., Huang, G., Hromas, R., Konopleva, M., Zheng, G., & Zhou, D.
- Affiliations
- University of Florida (US)
- The University of Texas MD Anderson Cancer Center (US)
- Columbia University (US)
- Children's Hospital Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Zheng, Guangrong
- Zhou, Daohong
- ORCID
- Khan, Sajid
- Zhang, Xuan
- Lv, Dongwen
- Zhang, Qi
- He, Yonghan
- Zhang, Peiyi
- Liu, Xingui
- Thummuri, Dinesh
- Yuan, Yaxia
- Pei, Jing
- Zhang, Weizhou
- Sharma, Abhisheak
- McCurdy, Christopher R.
- Kuruvilla, Vinitha M.
- Baran, Natalia
- Ferrando, Adolfo A.
- Kim, Yong-mi
- Houghton, Peter J.
- Huang, Guangcun
- Hromas, Robert
- Konopleva, Marina
- Zheng, Guangrong
- Zhou, Daohong
- Venue
- Nature Medicine
- Published
- 2019-12
- Volume
- 25
- Issue
- 12
- Pages
- 1938-1947
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6898785
- OpenAlex
- W2990669650
- Cited by
- 688
- References
- 63
- Citations by year
- 2026: 98 · 2025: 127 · 2024: 116 · 2023: 103 · 2022: 105 · 2021: 83 · 2020: 55
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH
- CPRIT
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Bcl-xL, PROTACs, VHL E3 ubiquitin ligase, thrombocytopenia, navitoclax, platelet toxicity, leukemia, tumor xenografts, BCL-2 inhibitor, on-target toxicity
- MeSH terms
- Aniline Compounds, Animals, Antineoplastic Agents, Blood Platelets, Humans, Sulfonamides, Thrombocytopenia, Gene Expression Regulation, Neoplastic, bcl-X Protein, Mice, Von Hippel-Lindau Tumor Suppressor Protein, Proteolysis, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
